http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2721419-C2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7aaea2e6a1d9bdb1c843bfe784e79c9e |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0459 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B59-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 |
filingDate | 2016-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d944063e505de3f223fbd1a3f0ce3df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73ea90f4e2550b464f98301117acee33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7911747ab30a8cd14f8624bddc602667 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ef38aa43cd78d44fdc296690b3b217b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12dc31b9407b9a29ac7a08286467e352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b658d727037bc451ea815222d4238f4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddbc35451f58159f85ed40beda957ac6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0248c53360134fccbcdd7aff66758f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74cac9c84dec0e0216ca5bc0720b3a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_134bdc731c32a8fb5953274f6487674a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f1ab5658f58e95749ac1fa6dc5b1947 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f759b28c9e34363d9a16b4fceb5a158f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_472c48386eba5d9302868310cdc15cd4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e579612aa7aca6975130e4758bdbe1b |
publicationDate | 2020-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2721419-C2 |
titleOfInvention | Probing proteins of hentingin protein |
abstract | FIELD: pharmaceuticals.SUBSTANCE: invention relates to a radiopharmaceutical comprising a compound of formula Ior a pharmaceutically acceptable salt thereof. In formula I: m is equal to 0, 1 or 2; n is 1 or 2; J is C (=O) or -CH-; X is S or N; Y is CH or N; Z is CH; W is N or S; each Ris independently selected from halogen, Calkoxy, hydroxyl group, Caryl, 5–10-member heteroaryl containing one or more heteroatoms selected from N, O and S, Ccycloalkoxy or Calkyl, where each Calkoxy, Ccycloalkoxy, Calkyl, Caryl or 5–10-member heteroaryl is optionally substituted with one, two or three groups independently selected from Calkoxy, Calkenyl, -NRR, halogen or 5–10-member heteroaryl containing one or more heteroatoms selected from N, O and S, optionally substituted with one to three Calkoxy; Ris hydrogen or Calkyl; and Ris Calkyl, Caryl, aralkyl, 3–10-member heterocycloalkyl containing one or more heteroatoms selected from N, O and S, 3–10-member heterocycloalkenyl, containing one or more heteroatoms selected from N, O and S, 5–10-member heteroaryl or heteroaralkyl, each of which is optionally substituted with one, two or three groups, independently selected from a hydroxyl group, Calkoxy, optionally substituted with Calkoxy or halogen, Calkyl, optionally substituted with halogen, halogen, 5–10-member heteroaryl, containing one or more heteroatoms selected from N, O and S, -(CH)NRR, oxo, cyano, or -C(O)-NRR, or Rand Rtogether with the nitrogen atom, to which they are bonded, form 5–10-member heterocycloalkyl ring, optionally substituted with one, two or three groups independently selected from hydroxy, Calkoxy, Calkyl, halogen or -C(O)-NRR; t is equal to 0, 1 or 2; Ris independently selected from hydrogen or Calkyl; Ris independently selected from hydrogen or Calkyl. Compound of formula I or its pharmaceutically acceptable salt is labeled (a) by one or more positron-active radionuclides. Also disclosed are a method of producing diagnostic images and compounds of formula I.EFFECT: compound of formula I possesses kinetics of binding aggregates of HTT protein or aggregates of β-amyloid protein and is suitable for their functioning as effective radiopharmaceuticals.41 cl, 6 dwg, 23 tbl, 24 ex |
priorityDate | 2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 419.